Previously, our team demonstrated that down-regulation of CYP1A2 impaired the 17β-estradiol (E2) metabolism, weakening E2-mediated tumor suppression, which contributed to HCC progression 16. The gene discussed is CYP1A2; the disease is neoplasm.